Captopril-polyethyleneimine conjugate modified gold nanoparticles for co-delivery of drug and gene in anti-angiogenesis breast cancer therapy

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA-Cancer J. Clin. 2012;62:10–29.
   PubMed Web of Science ®Google Scholar
• Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell. 2006;127:679–695. 10.1016/j.cell.2006.11.001
   PubMed Web of Science ®Google Scholar
• Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010;28:341–347. 10.1038/nbt.1618
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257. 10.1038/35025220
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995;1:27–30. 10.1038/nm0195-27
   PubMed Web of Science ®Google Scholar
• Mayer RJ. Two steps forward in the treatment of colorectal cancer. New Engl. J. Med. 2004;350:2406–2408. 10.1056/NEJMe048098
   PubMed Web of Science ®Google Scholar
• Meng H, Xing G, Sun B, et al. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano. 2010;4:2773–2783. 10.1021/nn100448z
   PubMed Web of Science ®Google Scholar
• Murata N, Takashima Y, Toyoshima K, et al. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. Control. Release. 2008;126:246–254. 10.1016/j.jconrel.2007.11.017
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber H-P, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004;3:391–400. 10.1038/nrd1381
   PubMed Web of Science ®Google Scholar
• Kim SH, Jeong JH, Lee SH, et al. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release. 2006;116:123–129. 10.1016/j.jconrel.2006.05.023
   PubMed Web of Science ®Google Scholar
• Amaral SL, Papanek PE, Greene AS. Angiotensin II and VEGF are involved in angiogenesis induced by short-term exercise training. Am. J. Physiol. Heart Circ. Physiol. 2001;281:A614.
   Google Scholar
• Higgins RD, Yan Y, Geng Y, et al. Captopril and vascular endothelial growth factor in a mouse model of retinopathy. Curr. Eye Res. 2003;27:123-129. 10.1076/ceyr.27.2.123.15955
   PubMed Web of Science ®Google Scholar
• Kowala MC, Valentine M, Recce R, et al. Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril. J. Cardiovasc. Pharm. 1998;32:29–38. 10.1097/00005344-199807000-00005
   PubMed Web of Science ®Google Scholar
• Lewis DL, Hagstrom JE, Loomis AG, et al. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 2002;32:107–108. 10.1038/ng944
   PubMed Web of Science ®Google Scholar
• Martinez J, Patkaniowska A, Urlaub H, et al. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell. 2002;110:563–574. 10.1016/S0092-8674(02)00908-X
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003;55:329–347. 10.1016/S0169-409X(02)00228-4
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao S, Ye W-H, et al. Co-delivery of drugs and DNA from cationic core–shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mat. 2006;5:791–796. 10.1038/nmat1737
   PubMed Web of Science ®Google Scholar
• Novo L, Rizzo LY, Golombek SK, et al. Decationized polyplexes as stable and safe carrier systems for improved biodistribution in systemic gene therapy. J. Control. Release. 2014;195:162–175. 10.1016/j.jconrel.2014.08.028
   PubMed Web of Science ®Google Scholar
• Grayson ACR, Doody AM, Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharmaceut. Res. 2006;23:1868–1876. 10.1007/s11095-006-9009-2
   PubMed Web of Science ®Google Scholar
• Wang C, Bao X, Ding X, et al. A multifunctional self-dissociative polyethyleneimine derivative coating polymer for enhancing the gene transfection efficiency of DNA/polyethyleneimine polyplexes in vitro and in vivo. Polym. Chem. 2015;6:780–796. 10.1039/C4PY01135J
   Web of Science ®Google Scholar
• Connor EE, Mwamuka J, Gole A, et al. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2005;1:325–327. 10.1002/(ISSN)1613-6829
   PubMed Web of Science ®Google Scholar
• Ghosh P, Han G, De M, et al. Gold nanoparticles in delivery applications. Adv. Drug Deliv. Rev. 2008;60:1307–1315. 10.1016/j.addr.2008.03.016
   PubMed Web of Science ®Google Scholar
• Bao X, Wang W, Wang C, et al. A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy. Biomaterials. 2014;35:8450–8466. 10.1016/j.biomaterials.2014.06.025
   PubMed Web of Science ®Google Scholar
• Lee SH, Bae KH, Kim SH, et al. Amine-functionalized gold nanoparticles as non-cytotoxic and efficient intracellular siRNA delivery carriers. Int. J. Pharm. 2008;364:94–101. 10.1016/j.ijpharm.2008.07.027
   PubMed Web of Science ®Google Scholar
• Liu Y, Shipton MK, Ryan J, et al. Synthesis, stability, and cellular internalization of gold nanoparticles containing mixed peptide-poly (ethylene glycol) monolayers. Anal. Chem. 2007;79:2221–2229. 10.1021/ac061578f
   PubMed Web of Science ®Google Scholar
• Liu J, Jiang X, Xu L, et al. Novel reduction-responsive cross-linked polyethylenimine derivatives by click chemistry for nonviral gene delivery. Bioconjugate Chem. 2010;21:1827–1835. 10.1021/bc100191r
   PubMed Web of Science ®Google Scholar
• Limbach LK, Li Y, Grass RN, et al. Oxide nanoparticle uptake in human lung fibroblasts: effects of particle size, agglomeration, and diffusion at low concentrations. Environ. Sci. Technol. 2005;39:9370–9376.
   PubMed Web of Science ®Google Scholar
• Lv H, Zhang S, Wang B, et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release. 2006;114:100–109. 10.1016/j.jconrel.2006.04.014
   PubMed Web of Science ®Google Scholar
• Lee M, Nah J-W, Kwon Y, et al. Water-soluble and low molecular weight chitosan-based plasmid DNA delivery. Pharm. Res. 2001;18:427–431. 10.1023/A:1011037807261
   PubMed Web of Science ®Google Scholar
• Amaya K, Ohta T, Kitagawa H, et al. Angiotensin II activates MAP kinase and NF-κB through angiotensin II type I receptor in human pancreatic cancer cells. Int. J. Oncol. 2004;25:849–856.
   PubMed Web of Science ®Google Scholar
• Anandanadesan R, Gong Q, Chipitsyna G, et al. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J. Gastrointest. Surg. 2008;12:57–66. 10.1007/s11605-007-0403-9
   PubMed Web of Science ®Google Scholar
• Takei Y, Kadomatsu K, Yuzawa Y, et al. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 2004;64:3365–3370. 10.1158/0008-5472.CAN-03-2682
   PubMed Web of Science ®Google Scholar
• Kosugi M, Miyajima A, Kikuchi E, et al. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin. Cancer Res. 2006;12:2888–2893. 10.1158/1078-0432.CCR-05-2213
   PubMed Web of Science ®Google Scholar